• Exclusive global rights for Neurizon to utilize Elanco's IP and data package for monepantel
• Significantly reduces development costs and accelerates timelines for NUZ-001
• Provides clear pathway for accelerated global commercialization of NUZ-001

Neurizon Therapeutics Limited (ASX: NUZ) has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. This license agreement provides Neurizon with exclusive global rights to Elanco's data package and related intellectual property for monepantel, allowing Neurizon to develop and commercialize NUZ-001 and its related compounds for the treatment of neurodegenerative diseases in humans. The agreement includes a nominal upfront licensing fee, milestone payments totaling up to $80.95 million, and tiered single-digit royalties on global net sales. Importantly, the agreement significantly reduces Neurizon's near-term development costs and accelerates the development timelines for NUZ-001 by providing access to Elanco's extensive package of non-clinical studies and manufacturing data. This strategic milestone also strengthens Neurizon's regulatory foundations, as the data package supports future clinical trials, potential regulatory approvals, and global market entry. The next step in the collaboration is for Neurizon and Elanco to finalize a supply agreement, which is expected in the second half of 2025.

Neurizon expects to receive up to $80.95 million in total development and sales milestone payments from Elanco, with the first milestone payments becoming due upon regulatory approvals and the commencement of commercial sales of NUZ-001.

The exclusive global licensing agreement with Elanco represents a critical inflection point for Neurizon, significantly strengthening the company's strategic outlook for the development, manufacturing, and potential future commercialization of NUZ-001. This agreement provides Neurizon with a clear pathway to accelerate the global commercialization of its lead investigational therapy for neurodegenerative diseases.